CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Experiences in the treatment of advanced hepatocellular carcinoma (HCC) with sorafenib beyond the SHARP trial–Patients with liver cirrhosis Child Pugh B/C and after liver transplantation
DOI 10.1055/s-2008-1037677
Bibliografische Angaben
Nachweis in CareLit
Autor:innenMA Wörns, H Schulze-Bergkamen, H Schulze-Bergkamen, M Schuchmann, M Schuchmann, C Düber, C Düber, G Otto, G Otto, PR Galle, PR Galle, A Weinmann
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Patients (pts) with advanced hepatocellular carcinoma (HCC) not eligible for curative treatments such as resection or liver transplantation have a dismal prognosis with survival rates less than six months. Sorafenib (Nexavar®, Bayer Health Care, Germany), a novel multikinase inhibitor blocking tumor cell proliferation and angiogenesis, was recently shown to provide a survival benefit in Child-Pugh A pts with a…
Zitieren
Zitierempfehlung
MA Wörns, H Schulze-Bergkamen, H Schulze-Bergkamen, M Schuchmann, M Schuchmann, C Düber, C Düber, G Otto, G Otto, PR Galle, PR Galle, A Weinmann (2008) Experiences in the treatment of advanced hepatocellular carcinoma (HCC) with sorafenib beyond the SHARP trial–Patients with liver cirrhosis Child Pugh B/C and after liver transplantation. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-2008-1037677
Mit CareLit weiterarbeiten